<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742673</url>
  </required_header>
  <id_info>
    <org_study_id>U11543</org_study_id>
    <nct_id>NCT04742673</nct_id>
  </id_info>
  <brief_title>Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study</brief_title>
  <acronym>MENDING</acronym>
  <official_title>Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proof-of-concept study examines whether the acute brain dysfunction that occurs in&#xD;
      critically ill patients is improved by administration of intravenous guanfacine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Delirium during critical illness is, to date, the primary potentially modifiable risk factor&#xD;
      for acquired dementia after critical illness (ADRD). There are, however, no Food and Drug&#xD;
      Administration (FDA) approved medications to mitigate delirium. Benzodiazepines are&#xD;
      ineffective at reducing the incidence or duration of delirium, and on the contrary, increase&#xD;
      the risk. Furthermore, large randomized controlled studies have shown that antipsychotic&#xD;
      agents have no effect (vs. placebo) on delirium duration, mechanical ventilation, hospital&#xD;
      length of stay, or death. Therefore, current clinical practice guidelines no longer recommend&#xD;
      routine use of benzodiazepines or antipsychotics for treatment of delirium. Despite these&#xD;
      recommendations, benzodiazepine, antipsychotics, and other drugs are routinely prescribed to&#xD;
      critically ill patients due to the urgent clinical need to control delirium symptoms. The&#xD;
      alpha-2 agonist dexmedetomidine is the most successful agent for delirium identified to date.&#xD;
      However, it is typically administered as a continuous infusion and requires ICU-level&#xD;
      monitoring due to hypotension and bradycardia risks. The delirium sparing benefits of&#xD;
      dexmedetomidine have been postulated to result from alpha-2 agonist mediated modulation of&#xD;
      CNS inflammation, microcirculatory blood flow, and biomimetic sleep.&#xD;
&#xD;
      The alpha-2 agonist guanfacine, an FDA-approved medication for use in hypertension and&#xD;
      attention deficit hyperactivity disorder, has a higher selectivity for the alpha-2A receptor&#xD;
      in the central nervous system. Thus, delirium sparing benefits may be improved with&#xD;
      guanfacine while reducing systemic effects. Further, instead of a continuous infusion, the&#xD;
      pharmacokinetic and pharmacodynamic properties of guanfacine favor a twice a day bolus dosing&#xD;
      schedule. This Maximizing trEatment of Neurological Dysfunction using INtravenous Guanfacine&#xD;
      (MENDING) study will investigate the benefits of intravenous (IV) guanfacine. In this phase&#xD;
      II proof-of-concept trial of IV guanfacine vs. placebo for the treatment of critical illness&#xD;
      delirium, the following specific aims will be tested in critically ill patients with&#xD;
      delirium:&#xD;
&#xD;
      Aim 1: To determine whether IV guanfacine will increase the number of days alive without&#xD;
      delirium and coma (DCFDs) over 14 days relative to placebo.&#xD;
&#xD;
      Aim 2: To evaluate whether IV guanfacine twice a day will increase days alive and free of&#xD;
      mechanical ventilation (VFDs) and days alive and free of the ICU (IFDs) over 28 days relative&#xD;
      to placebo.&#xD;
&#xD;
      Aim 3: To assess whether IV guanfacine can reduce the development of ADRD after critical&#xD;
      illness.&#xD;
&#xD;
      Identifying a safe and effective treatment for delirium would have exponential benefits to&#xD;
      patients, families, healthcare, and society. This first study of IV guanfacine builds upon&#xD;
      extensive research regarding the benefits of alpha-2 agonists for brain dysfunction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days alive without delirium or coma</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days alive and free of mechanical ventilation</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and free of the intensive care unit</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>up to 180 days after hospital discharge</time_frame>
    <description>Telephone Montreal Cognitive Assessment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Days alive and free of the hospital</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>up to 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Physical Function</measure>
    <time_frame>up to 180 days after hospital discharge</time_frame>
    <description>Patient-Reported Outcomes Measurement Information System V.1.2-Physical Function 8b</description>
  </other_outcome>
  <other_outcome>
    <measure>Global Health</measure>
    <time_frame>up to 180 days after hospital discharge</time_frame>
    <description>Patient-Reported Outcomes Measurement Information System V.1.1-Global</description>
  </other_outcome>
  <other_outcome>
    <measure>Pain Interference</measure>
    <time_frame>up to 180 days after hospital discharge</time_frame>
    <description>Patient-Reported Outcomes Measurement Information System V.1.0-Pain Interference 8a</description>
  </other_outcome>
  <other_outcome>
    <measure>Applied Cognition</measure>
    <time_frame>up to 180 days after hospital discharge</time_frame>
    <description>Patient-Reported Outcomes Measurement Information System V.1.0-Applied Cognition</description>
  </other_outcome>
  <other_outcome>
    <measure>Sleep</measure>
    <time_frame>up to 180 days after hospital discharge</time_frame>
    <description>Patient-Reported Outcomes Measurement Information System V.1.0-Sleep Disturbance</description>
  </other_outcome>
  <other_outcome>
    <measure>Co-administration of sedatives, analgesics, and antipsychotics</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Frequency and quantity of administration</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypotension</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Refractory systolic blood pressure &lt; 90 mm Hg or Mean arterial blood pressure &lt; 65 mm Hg despite ongoing ICU therapies</description>
  </other_outcome>
  <other_outcome>
    <measure>Bradycardia</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Heart rate &lt; 60 beats per minute despite ongoing ICU therapies</description>
  </other_outcome>
  <other_outcome>
    <measure>Mental status</measure>
    <time_frame>up to 14 days</time_frame>
    <description>New, acute neurologic disturbances such as blurred vision, dizziness, weakness, or vertigo</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Critical Illness</condition>
  <condition>Delirium</condition>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will flow through the trial in the following manner:&#xD;
Consent in ICU: perform required inclusion/exclusion assessments; discuss study goals, activities, and requirements; obtain informed consent&#xD;
Pre-randomization phase: twice daily assessments of mental status&#xD;
Randomize delirious patients: IV guanfacine or placebo&#xD;
Interventional Trial phase: study drug administration, mental status assessments, safety monitoring&#xD;
Blood draws: collect blood samples on Interventional Trial Phase days 1 and 2&#xD;
Follow-up assessments: telephone and online questionnaires at 30, 90, and 180 days after hospital discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Guanfacine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will flow through the trial in the following manner:&#xD;
Consent in ICU: perform required inclusion/exclusion assessments; discuss study goals, activities, and requirements; obtain informed consent&#xD;
Pre-randomization phase: twice daily assessments of mental status&#xD;
Randomize delirious patients: IV guanfacine or placebo&#xD;
Interventional Trial phase: study drug administration, mental status assessments, safety monitoring&#xD;
Blood draws: collect blood samples on Interventional Trial Phase days 1 and 2&#xD;
Follow-up assessments: telephone and online questionnaires at 30, 90, and 180 days after hospital discharge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guanfacine</intervention_name>
    <description>Patients randomized to the IV Guanfacine arm will receive intravenous guanfacine when they exhibit ICU delirium.</description>
    <arm_group_label>IV Guanfacine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients randomized to the placebo arm will receive intravenous normal saline when they exhibit ICU delirium.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. adult patients (â‰¥ 18 years old)&#xD;
&#xD;
          2. requiring admission to an ICU&#xD;
&#xD;
          3. for treatment of respiratory failure (e.g., mechanical ventilation, non-invasive&#xD;
             positive pressure ventilation [NIPPV], Extracorporeal Membrane Oxygenation [ECMO],&#xD;
             optiflow) and/or for treatment of shock (e.g., vasopressors, ECMO, intra-aortic&#xD;
             balloon pump [IABP]).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. allergic to guanfacine, clonidine, or dexmedetomidine&#xD;
&#xD;
          2. on home antipsychotics who, therefore, require continuing antipsychotic administration&#xD;
             in the hospital&#xD;
&#xD;
          3. present history of 2nd or 3rd degree heart block, or persistent bradycardia &lt; 50&#xD;
             beats/minute that requires intervention (e.g., atropine, glycopyrrolate). If patient&#xD;
             has a pacemaker for bradyarrythmias, then patient does not meet this exclusion&#xD;
             criterion and may be enrolled.&#xD;
&#xD;
          4. co-enrolled in another interventional trial examining similar outcomes or in a study&#xD;
             that does not allow co-enrollment&#xD;
&#xD;
          5. expected death within 24 hours of enrollment or lack of commitment to aggressive&#xD;
             treatment by family or the medical team (e.g., likely withdrawal of life support&#xD;
             measures within 24 hours of screening)&#xD;
&#xD;
          6. acute or subacute neurologic deficit that is expected to make the patient incapable of&#xD;
             living independently after hospital discharge due to cognitive deficits (e.g., stroke,&#xD;
             intracranial hemorrhage, cranial trauma, intracranial malignancy, anoxic brain injury,&#xD;
             cerebral edema).&#xD;
&#xD;
          7. dementia or other chronic neurologic disease or disorder that makes the patient&#xD;
             incapable of living independently at baseline&#xD;
&#xD;
          8. active substance abuse, psychotic disorder, or homelessness without a secondary&#xD;
             contact person (which would make long-term follow-up difficult)&#xD;
&#xD;
          9. blindness or deafness (which would prevent assessment of the study's outcomes)&#xD;
&#xD;
         10. pregnancy or breastfeeding&#xD;
&#xD;
         11. prisoner&#xD;
&#xD;
         12. inability to start informed consent process within 72 hours from the time that all&#xD;
             inclusion criteria were met&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Hughes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Hughes, MD</last_name>
    <phone>6153436268</phone>
    <email>christopher.hughes@vumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher G Hughes, MD</last_name>
      <phone>615-343-6268</phone>
      <email>christopher.hughes@vumc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Christopher G Hughes</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guanfacine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

